Plozasiran治疗持续性乳糜微粒血症及胰腺炎风险
这项3期随机对照试验纳入75例持续性乳糜微粒血症患者(伴或不伴基因诊断),随机接受皮下plozasiran 25mg、50mg或安慰剂,每3个月一次,共12个月。主要终点为10个月时空腹甘油三酯较基线的中位百分比变化:25mg组-80%、50mg组-78%、安慰剂组-17%(P<0.001)。关键次要终点包括10个月和12个月空腹甘油三酯及载脂蛋白C-III变化、急性胰腺炎发生率,plozasiran组均优于安慰剂组;急性胰腺炎OR 0.17(95%CI 0.03-0.94;P=0.03)。不良事件风险组间相似,最常见为腹痛、鼻咽炎、头痛和恶心;严重和重度不良事件在plozasiran组较少见;部分基线糖尿病前期或糖尿病患者出现高血糖。
要点
- 25mg plozasiran组10个月空腹甘油三酯中位变化-80%,50mg组-78%,安慰剂组-17%(P<0.001)。
- plozasiran组急性胰腺炎发生率低于安慰剂组(OR 0.17;95%CI 0.03-0.94;P=0.03)。
- 给药方案:皮下注射25mg或50mg,每3个月一次,共12个月。
- 不良事件风险组间相似,最常见腹痛、鼻咽炎、头痛、恶心;部分基线糖尿病前期或糖尿病患者出现高血糖。
适用人群与场景
- 持续性乳糜微粒血症患者(伴或不伴基因诊断),基线中位甘油三酯2044 mg/dL。
处置流程与药物剂量
- 皮下注射plozasiran 25mg或50mg,每3个月一次,共12个月。
研究设计与关键结果
- 3期随机对照试验,75例持续性乳糜微粒血症患者随机接受皮下plozasiran 25mg、50mg或安慰剂,每3个月一次,共12个月。
- 主要终点(10个月空腹甘油三酯较基线中位百分比变化):25mg组-80%,50mg组-78%,安慰剂组-17%(P<0.001)。
- 关键次要终点包括10个月和12个月空腹甘油三酯及载脂蛋白C-III变化、急性胰腺炎发生率,plozasiran组均优于安慰剂组。
- 急性胰腺炎发生率:OR 0.17(95%CI 0.03-0.94;P=0.03)。
- 不良事件风险组间相似;最常见不良事件为腹痛、鼻咽炎、头痛、恶心;严重和重度不良事件在plozasiran组较安慰剂组少见;部分基线糖尿病前期或糖尿病患者出现高血糖。
证据类型、等级与局限
- 证据类型:3期随机对照试验(PALISADE,NCT05089084)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于持续性乳糜微粒血症患者,皮下注射plozasiran 25mg或50mg每3个月一次共12个月可显著降低空腹甘油三酯水平并降低急性胰腺炎发生率。
- 对基线糖尿病前期或糖尿病患者使用plozasiran时需注意高血糖风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides.
METHODS: In a phase 3 trial, we randomly assigned 75 patients with persistent chylomicronemia (with or without a genetic diagnosis) to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months. The primary end point was the median percent change from baseline in the fasting triglyceride level at 10 months. Key secondary end points were the percent change in the fasting triglyceride level from baseline to the mean of values at 10 months and 12 months, changes in the fasting apolipoprotein C-III level from baseline to 10 months and 12 months, and the incidence of acute pancreatitis.
RESULTS: At baseline, the median triglyceride level was 2044 mg per deciliter. At 10 months, the median change from baseline in the fasting triglyceride level (the primary end point) was -80% in the 25-mg plozasiran group, -78% in the 50-mg plozasiran group, and -17% in the placebo group (P<0.001). The key secondary end points showed better results in the plozasiran groups than in the placebo group, including the incidence of acute pancreatitis (odds ratio, 0.17; 95% confidence interval, 0.03 to 0.94; P = 0.03). The risk of adverse events was similar across groups; the most common adverse events were abdominal pain, nasopharyngitis, headache, and nausea. Severe and serious adverse events were less common with plozasiran than with placebo. Hyperglycemia with plozasiran occurred in some patients with prediabetes or diabetes at baseline.
CONCLUSIONS: Patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Funded by Arrowhead Pharmaceuticals; PALISADE ClinicalTrials.gov number, NCT05089084.).
参考来源
- Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med. 2024. PMID: 39225259. doi:10.1056/NEJMoa2409368
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。